Plasma Thermogram Parameters Differentiate Status and Overall Survival of Melanoma Patients

Melanoma is the fifth most common cancer in the United States and the deadliest of all skin cancers. Even with recent advancements in treatment, there is still a 13% two-year recurrence rate, with approximately 30% of recurrences being distant metastases. Identifying patients at high risk for recurrence or advanced disease is critical for optimal clinical decision-making. Currently, there is substantial variability in the selection of screening tests and imaging, with most modalities characterized by relatively low accuracy. In the current study, we built upon a preliminary examination of differential scanning calorimetry (DSC) in the melanoma setting to examine its utility for diagnostic and prognostic assessment. Using regression analysis, we found that selected DSC profile (thermogram) parameters were useful for differentiation between melanoma patients and healthy controls, with more complex models distinguishing melanoma patients with no evidence of disease from patients with active disease. Thermogram features contributing to the third principal component (PC3) were useful for differentiation between controls and melanoma patients, and Cox proportional hazards regression analysis indicated that PC3 was useful for predicting the overall survival of active melanoma patients. With the further development and optimization of the classification method, DSC could complement current diagnostic strategies to improve screening, diagnosis, and prognosis of melanoma patients.

[1]  R. Martí,et al.  Association of TYR SNP rs1042602 with Melanoma Risk and Prognosis , 2022, Life.

[2]  M. Merchant,et al.  The Utility of Differential Scanning Calorimetry Curves of Blood Plasma for Diagnosis, Subtype Differentiation and Predicted Survival in Lung Cancer , 2021, Cancers.

[3]  Eric A. Smith,et al.  Molecular Biomarkers for Melanoma Screening, Diagnosis and Prognosis: Current State and Future Prospects , 2021, Frontiers in Medicine.

[4]  S. Swetter,et al.  NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

[5]  O. Abián,et al.  Thermal Liquid Biopsy (TLB) Focused on Benign and Premalignant Pancreatic Cyst Diagnosis , 2020, Journal of personalized medicine.

[6]  L. Kiemeney,et al.  Association between a 46-SNP Polygenic Risk Score and melanoma risk in Dutch patients with familial melanoma , 2020, Journal of Medical Genetics.

[7]  V. Andreotti,et al.  Current State of Target Treatment in BRAF Mutated Melanoma , 2020, Frontiers in Molecular Biosciences.

[8]  J. Geisler,et al.  BRAF mutational status as a prognostic marker for survival in malignant melanoma: a systematic review and meta-analysis , 2020, Acta oncologica.

[9]  Jeffrey E. Lee,et al.  Genetic variants in PDSS1 and SLC16A6 of the ketone body metabolic pathway predict cutaneous melanoma‐specific survival , 2020, Molecular carcinogenesis.

[10]  D. Lőrinczy,et al.  Deconvoluted plasma DSC curves on patients with psoriasis , 2020, Journal of Thermal Analysis and Calorimetry.

[11]  Sami Ekici,et al.  Breast cancer diagnosis using thermography and convolutional neural networks. , 2019, Medical hypotheses.

[12]  O. Abián,et al.  Thermal Liquid Biopsy (TLB): A Predictive Score Derived from Serum Thermograms as a Clinical Tool for Screening Lung Cancer Patients , 2019, Cancers.

[13]  H. Williams,et al.  Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma. , 2019, The Cochrane database of systematic reviews.

[14]  D. Faroongsarng,et al.  Thermally Induced Denaturing Energetics of Human Blood Plasma Albumin by Differential Scanning Calorimetry (DSC) as an Indicator for Breast Cancer Diagnosis in Female Patients , 2019, AAPS PharmSciTech.

[15]  O. Abián,et al.  Thermal liquid biopsy for monitoring melanoma patients under surveillance during treatment: A pilot study. , 2018, Biochimica et biophysica acta. General subjects.

[16]  P. Tsvetkov,et al.  Differential scanning calorimetry of plasma in glioblastoma: toward a new prognostic / monitoring tool , 2018, Oncotarget.

[17]  I. Chmielewska,et al.  Blood Serum Calorimetry Indicates the Chemotherapeutic Efficacy in Lung Cancer Treatment , 2017, Scientific Reports.

[18]  William H. Ward,et al.  Cutaneous Melanoma: Etiology and Therapy , 2017 .

[19]  K. B. Kulasekera,et al.  Characterization and classification of lupus patients based on plasma thermograms , 2017, PloS one.

[20]  Jeffrey E Gershenwald,et al.  Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual , 2017, CA: a cancer journal for clinicians.

[21]  J. Taube,et al.  Melanoma subtypes demonstrate distinct PD-L1 expression profiles. , 2017, Laboratory investigation; a journal of technical methods and pathology.

[22]  C. Cockerell,et al.  An independent validation of a gene expression signature to differentiate malignant melanoma from benign melanocytic nevi , 2016, Cancer.

[23]  N. Garbett,et al.  Differential scanning calorimetry as a complementary diagnostic tool for the evaluation of biological samples. , 2016, Biochimica et biophysica acta.

[24]  D. Lőrinczy,et al.  Harmful effect of neoadjuvant chemotherapy monitoring by DSC on breast cancer patients’ blood plasma , 2016, Journal of Thermal Analysis and Calorimetry.

[25]  J. Taube,et al.  Diagnostic utility of 5‐hydroxymethylcytosine immunohistochemistry in melanocytic proliferations , 2015, Journal of cutaneous pathology.

[26]  P. Marcorelles,et al.  A p16-Ki-67-HMB45 immunohistochemistry scoring system as an ancillary diagnostic tool in the diagnosis of melanoma , 2015, Diagnostic Pathology.

[27]  A. Gutin,et al.  Clinical validation of a gene expression signature that differentiates benign nevi from malignant melanoma , 2015, Journal of cutaneous pathology.

[28]  J. Chaires,et al.  Clinical application of plasma thermograms. Utility, practical approaches and considerations. , 2015, Methods.

[29]  J. Klein,et al.  Detection of Cervical Cancer Biomarker Patterns in Blood Plasma and Urine by Differential Scanning Calorimetry and Mass Spectrometry , 2014, PloS one.

[30]  L. Hansen,et al.  Differential scanning calorimetry of gliomas: a new tool in brain cancer diagnostics? , 2013, Neurosurgery.

[31]  S. Taneva,et al.  Calorimetry-based profiling of blood plasma from colorectal cancer patients. , 2012, Biochimica et biophysica acta.

[32]  M. Birtwistle,et al.  Novel Somatic Mutations to PI3K Pathway Genes in Metastatic Melanoma , 2012, PloS one.

[33]  F. Marincola,et al.  The role of BRAF V600 mutation in melanoma , 2012, Journal of Translational Medicine.

[34]  D. Lőrinczy,et al.  Differential scanning calorimetry (DSC) analysis of human plasma in melanoma patients with or without regional lymph node metastases , 2012, Journal of Thermal Analysis and Calorimetry.

[35]  S. Taneva,et al.  Microcalorimetry of blood serum proteome: a modified interaction network in the multiple myeloma case. , 2011, Analytical chemistry.

[36]  J. Reichrath,et al.  Vitamin D receptor (VDR) polymorphisms and skin cancer , 2011 .

[37]  D. Schadendorf,et al.  Polymorphisms in the CD28/CTLA4/ICOS genes: role in malignant melanoma susceptibility and prognosis? , 2009, Cancer Immunology, Immunotherapy.

[38]  J. Chaires,et al.  Differential scanning calorimetry of blood plasma for clinical diagnosis and monitoring. , 2009, Experimental and molecular pathology.

[39]  Charles X. Ling,et al.  Using AUC and accuracy in evaluating learning algorithms , 2005, IEEE Transactions on Knowledge and Data Engineering.

[40]  Daniel Pinkel,et al.  Classifying melanocytic tumors based on DNA copy number changes. , 2003, The American journal of pathology.

[41]  B K Armstrong,et al.  Melanoma of the skin. , 1984, British medical bulletin.